Weight Watchers Stock Soars on Eli Lilly Drug Deal

WW Stock Surges on New GLP-1 Medication Offering

Weight Watchers, NASDAQ:WW, shares jumped 17% following the announcement that it will offer Eli Lilly’s newly FDA-approved oral GLP-1 medication, Foundayo, also known as orforglipron, through its comprehensive Med+ program.

Overview of the Strategic Partnership

The collaboration provides Med+ members with a once-daily, injection-free option for adults with obesity or weight-related medical issues. The medication will be offered alongside clinical care, insurance support, and the company's GLP-1 Success program. Self-pay pricing begins at $149 per month for the lowest dose.

Impact on Market Position

This partnership strengthens Weight Watchers' position in the evolving weight health landscape by integrating popular, FDA-approved treatments into its established behavioral support model. The company reported that members using its support program alongside a GLP-1 lost 29.1% more body weight on average than those without behavioral support.

Summary

By expanding its portfolio of GLP-1 treatments, Weight Watchers is capitalizing on the high demand for new-generation weight-loss drugs. This move is aimed at driving revenue growth and enhancing service offerings for clinically eligible members, signaling a clear strategic pivot in a competitive market.

FAQ

Q: Why did Weight Watchers stock increase?
A: The stock surged 17% after the company revealed it would offer Eli Lilly's new oral GLP-1 medication, Foundayo, through its Med+ program.

Q: What is Foundayo?
A: It is a once-daily, injection-free oral medication for adults with obesity or overweight conditions, developed by Eli Lilly and newly approved by the FDA.

Source: Investing.com